Mitchell Cole

Mitchell Cole provides a wide variety of healthcare stakeholders, including health plans, pharmaceutical manufacturers, patient groups, and trade associations, with data-driven analyses of the impacts of policy and regulatory changes.

Mitchell applies expertise in quantitative analysis, modeling, and the synthesis of healthcare data to advise clients on the effects of changes to the Medicare and Medicaid programs on patient access to care, the market landscape, and federal and state budgets.

Prior to joining Avalere, Mitchell worked at the U.S. Government Accountability Office, contributing to a review of several federal agencies. Prior to that, Mitchell worked as a policy analyst at The Commonwealth Institute for Fiscal Analysis, where he examined trends in a number of state policy areas, analyzed legislation under consideration, and developed data-driven policy recommendations.

Mitchell has an MPP and a BA in economics and international relations from the College of William and Mary.

Authored Content

New analysis from Avalere finds that HR3 could reduce federal spending by $737B and decrease manufacturer revenues by $1T for CY 2020–2029.

Avalere analysis finds that tying Medicare Part D manufacturer discounts to utilization in the catastrophic phase instead of in the coverage gap would have differential impacts by disease area.

As policymakers consider reforms to Part D, new Avalere analysis shows that congressional proposals to cap out-of-pocket (OOP) costs in the catastrophic phase are likely to reduce OOP for many beneficiaries

Avalere analysis finds that a larger proportion of beneficiaries taking a Part D cancer therapy reached catastrophic compared to all Part D enrollees.

The Center for American Progress (CAP) commissioned Avalere to evaluate ‘Medicare Extra’ as a package of reform polices implemented and phased in over time across the US healthcare system.

New Avalere analysis finds that shifting Part B-covered rheumatoid arthritis (RA) drugs to Part D benefit would increase the share of prescriptions occurring in the catastrophic phase for impacted beneficiaries by more than 5 times.

New Avalere analysis finds that beneficiaries enrolled in Employer Group Waiver Plans (EGWPs) have lower out-of-pocket (OOP) costs for select drugs than beneficiaries enrolled in other types of Part D plans.

New analysis from Avalere finds that 102 million individuals, not enrolled in major public programs like Medicaid or Medicare, have a pre-existing medical condition and could therefore face higher premiums or significant out-of-pocket costs if the ACA’s pre-existing condition protections were repealed.